Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
about
The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applicationsAnti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic ApproachesTumor antigen-specific monoclonal antibodies and induction of T-cell immunitySerum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomasEpigenetic control of the foxp3 locus in regulatory T cellsHigh level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas.CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression.The role of regulatory T cells in cancer.Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival.Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinomaCD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients.Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma.T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoringIntracellular CTLA4 and regulatory T cells in patients with laryngeal squamous cell carcinoma.Immune suppression in head and neck cancers: a reviewTumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study.The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns.Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinomaImmune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression.Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccinationFrequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling.Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells.Accumulation Mechanisms of CD4(+)CD25(+)FOXP3(+) Regulatory T Cells in EBV-associated Gastric CarcinomaStrong-arming immune regulation: suppressing regulatory T-cell function to treat cancers.Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity.Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck.Inverse immunological responses induced by allergic rhinitis and head and neck squamous cell carcinoma.Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapyTumor evasion from T cell surveillance.
P2860
Q26747516-97BE0C42-A9C4-4652-9F8A-854667B99073Q26774312-572BD5D2-66B4-4B50-A82C-7931C403E2F8Q27009908-4DADBFEE-2991-47F9-8235-A12797C1C1FFQ28728826-10F9A030-E36C-4478-96A2-3EB9642B326BQ33273617-D2F5C020-3740-4FA7-B163-58A415774737Q33597525-7470FAD0-E6DC-4D90-9A06-4DEA250D54ABQ33615788-12807247-4FC6-47F8-B8A4-04863657B9EBQ33631986-CCEE890E-6939-4FBF-AEA8-BF88B9268D45Q33818673-36FE7BC0-29C5-4469-9C04-388209D6E753Q33834337-2866E33C-9A62-462A-8058-24771E1C7182Q34083746-8FC8CA1D-516B-4B63-BA29-9B14029FB586Q34289206-15CC68D6-EC09-4628-9DD0-8BD93AA8BDFBQ34475726-A948E628-A12B-4F0D-87EA-00E2FEC77A43Q34557531-814EE43E-FE4C-4B66-9889-29A93EF39DB2Q34646640-A0D2B723-C7F2-4DCC-BED5-B6CA78588B87Q34700675-D93083D6-FD18-4C51-85F6-CAA57558A4B5Q34718331-AFE6B077-0D44-4400-95C5-7E2D8EAEC583Q35000396-775525EE-F3D3-418A-B7C2-C4DFC5D65C9DQ35067627-DD7C87F9-C651-4D0E-BA5D-C54E364271E1Q35203067-60DA6465-1A30-4AEE-8F39-26A99666A31FQ35384216-4B86506A-D9F8-4025-AFC2-385BA2184E28Q35451153-A46469BB-53F8-415F-B83B-0CB2EF44C58AQ35644535-0B3E1AEA-2EB9-4E3B-A042-8FC4745D97A8Q35674757-95EE32E6-D273-40E4-9DFE-6DAD906F6615Q36024702-A9E2DBAE-48ED-4B30-8969-AFE7F8013C46Q36049894-FAC8464B-C15F-4D84-9DB1-92CDD22CF8D0Q36230808-0B51A8AD-24F5-43B3-841A-A886E7C77D50Q36379628-CFA6DA7D-DF83-4BE1-98E4-8793E8E7BF87Q36512526-F21102CD-0F7B-4F71-AB75-C819A7CFD824Q36605447-A6F3D019-FDD3-4418-9FBD-6E019B864F1DQ36821572-7CC1353D-CF6F-4C69-8B9B-0A381E6782F7Q36834545-E5A5938D-EED6-4C5A-AB03-2F8D2CA352DAQ36973865-0B0077D3-ACCC-4B3E-A616-ABB4A8043610Q37323082-84AD8487-20DC-4AD0-A008-FBF4384DB895Q37334966-28E918B3-3F47-47F9-8C7D-77A96CAEEB01Q37506015-6A343A58-0904-455A-ABB0-86ECA983AB30Q37675926-E6F9249E-34B2-4E00-BD96-B6285E0CD790Q37684668-02C3F5E9-18BB-4D2F-BE95-7564B2228BBDQ37724053-D46B378D-218A-4435-BFCF-E6CC7D5ECCE9Q37970674-0E2792C1-5238-4FCA-9CAB-F317838CA11E
P2860
Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Characteristics of CD4+CD25+ r ...... ents with head and neck cancer
@ast
Characteristics of CD4+CD25+ r ...... ents with head and neck cancer
@en
type
label
Characteristics of CD4+CD25+ r ...... ents with head and neck cancer
@ast
Characteristics of CD4+CD25+ r ...... ents with head and neck cancer
@en
prefLabel
Characteristics of CD4+CD25+ r ...... ents with head and neck cancer
@ast
Characteristics of CD4+CD25+ r ...... ents with head and neck cancer
@en
P2093
P2860
P356
P1476
Characteristics of CD4+CD25+ r ...... ents with head and neck cancer
@en
P2093
C Schaefer
K Hoermann
T L Whiteside
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602407
P407
P577
2005-03-01T00:00:00Z